BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mohammed AJ, Alawaidy S, Bawikar S, Kurup PJ, Elamir E, Shaban MM, Sharif SM, van der Avoort HG, Pallansch MA, Malankar P, Burton A, Sreevatsava M, Sutter RW. Fractional Doses of Inactivated Poliovirus Vaccine in Oman. N Engl J Med 2010;362:2351-9. [DOI: 10.1056/nejmoa0909383] [Cited by in Crossref: 120] [Cited by in F6Publishing: 40] [Article Influence: 10.9] [Reference Citation Analysis]
Number Citing Articles
1 Rivera L, Pedersen RS, Peña L, Olsen KJ, Andreasen LV, Kromann I, Nielsen PI, Sørensen C, Dietrich J, Bandyopadhyay AS, Thierry-Carstensen B. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial. Lancet Infect Dis 2017;17:745-53. [PMID: 28454674 DOI: 10.1016/S1473-3099(17)30177-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
2 Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis 2014;210 Suppl 1:S439-46. [PMID: 24634499 DOI: 10.1093/infdis/jit601] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
3 Hung IFN, Yuen KY. Immunogenicity, safety and tolerability of intradermal influenza vaccines. Hum Vaccin Immunother 2018;14:565-70. [PMID: 28604266 DOI: 10.1080/21645515.2017.1328332] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
4 Mateen FJ, Shinohara RT, Sutter RW. Oral and inactivated poliovirus vaccines in the newborn: a review. Vaccine 2013;31:2517-24. [PMID: 22728224 DOI: 10.1016/j.vaccine.2012.06.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
5 Snider CJ, Zaman K, Estivariz CF, Yunus M, Weldon WC, Wannemuehler KA, Oberste MS, Pallansch MA, Wassilak SG, Bari TIA, Anand A. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial. Lancet 2019;393:2624-34. [PMID: 31104832 DOI: 10.1016/S0140-6736(19)30503-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Troy SB, Kouiavskaia D, Siik J, Kochba E, Beydoun H, Mirochnitchenko O, Levin Y, Khardori N, Chumakov K, Maldonado Y. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults. J Infect Dis 2015;211:1969-76. [PMID: 25567841 DOI: 10.1093/infdis/jiu841] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
7 Brickley EB, Connor RI, Wieland-Alter WF, Collett MS, Hartford M, Van Der Avoort H, Boesch AW, Weiner JA, Ackerman ME, McKinlay MA, Arita M, Bandyopadhyay AS, Modlin JF, Wright PF. Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden. BMJ Glob Health 2019;4:e001613. [PMID: 31543993 DOI: 10.1136/bmjgh-2019-001613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Hettinga J, Carlisle R. Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects. Vaccines (Basel) 2020;8:E534. [PMID: 32947966 DOI: 10.3390/vaccines8030534] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
9 Saleem AF, Mach O, Yousafzai MT, Khan A, Weldon WC, Oberste MS, Sutter RW, Zaidi AKM. Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan. Vaccine 2017;35:3209-14. [PMID: 28479178 DOI: 10.1016/j.vaccine.2017.04.075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
10 Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL. Preeradication vaccine policy options for poliovirus infection and disease control. Risk Anal 2013;33:516-43. [PMID: 23461599 DOI: 10.1111/risa.12019] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
11 Hickling JK, Jones KR, Friede M, Zehrung D, Chen D, Kristensen D. Intradermal delivery of vaccines: potential benefits and current challenges. Bull World Health Organ 2011;89:221-6. [PMID: 21379418 DOI: 10.2471/BLT.10.079426] [Cited by in Crossref: 106] [Cited by in F6Publishing: 45] [Article Influence: 10.6] [Reference Citation Analysis]
12 Schipper P, van der Maaden K, Romeijn S, Oomens C, Kersten G, Jiskoot W, Bouwstra J. Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles. Pharm Res 2016;33:2269-79. [PMID: 27317570 DOI: 10.1007/s11095-016-1965-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
13 Schnyder JL, De Pijper CA, Garcia Garrido HM, Daams JG, Goorhuis A, Stijnis C, Schaumburg F, Grobusch MP. Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis. Travel Med Infect Dis. 2020;37:101868. [PMID: 32898704 DOI: 10.1016/j.tmaid.2020.101868] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
14 Yousafzai MT, Saleem AF, Mach O, Baig A, Sutter RW, Zaidi AKM. Feasibility of conducting intradermal vaccination campaign with inactivated poliovirus vaccine using Tropis intradermal needle free injection system, Karachi, Pakistan. Heliyon 2017;3:e00395. [PMID: 29333501 DOI: 10.1016/j.heliyon.2017.e00395] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
15 Ma L, Cai W, Sun M, Cun Y, Zhou J, Liu J, Hu W, Zhang X, Song S, Jiang S, Liao G. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats. Hum Vaccin Immunother 2016;12:3125-31. [PMID: 27558963 DOI: 10.1080/21645515.2016.1214347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
16 Bandyopadhyay AS, Gast C, Rivera L, Sáez-Llorens X, Oberste MS, Weldon WC, Modlin J, Clemens R, Costa Clemens SA, Jimeno J, Rüttimann R. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. Lancet Infect Dis 2021;21:559-68. [PMID: 33284114 DOI: 10.1016/S1473-3099(20)30555-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Bullo UF, Mehraj J, Raza SM, Rasool S, Ansari NN, Shaikh AA, Phul ZA, Memon SA, Baloch RI, Baloch ZA, Chandio SA. An experience of mass administration of fractional dose inactivated polio vaccine through intradermal needle-free injectors in Karachi, Sindh, Pakistan. BMC Public Health 2021;21:44. [PMID: 33407294 DOI: 10.1186/s12889-020-10041-8] [Reference Citation Analysis]
18 Dey A, Molodecky NA, Verma H, Sharma P, Yang JS, Saletti G, Ahmad M, Bahl SK, Wierzba TF, Nandy RK, Deshpande JM, Sutter RW, Czerkinsky C. Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus. PLoS One 2016;11:e0146010. [PMID: 26730586 DOI: 10.1371/journal.pone.0146010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
19 Brickley EB, Wright PF. Maximising the impact of inactivated polio vaccines. Lancet Infect Dis 2017;17:680-1. [PMID: 28454675 DOI: 10.1016/S1473-3099(17)30236-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Markkanen P, Galligan C, Laramie A, Fisher J, Sama S, Quinn M. Understanding sharps injuries in home healthcare: The Safe Home Care qualitative methods study to identify pathways for injury prevention. BMC Public Health 2015;15:359. [PMID: 25885473 DOI: 10.1186/s12889-015-1673-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
21 Azman AS, Luquero FJ, Ciglenecki I, Grais RF, Sack DA, Lessler J. The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study. PLoS Med 2015;12:e1001867. [PMID: 26305226 DOI: 10.1371/journal.pmed.1001867] [Cited by in Crossref: 58] [Cited by in F6Publishing: 37] [Article Influence: 9.7] [Reference Citation Analysis]
22 Parker EP, Molodecky NA, Pons-Salort M, O'Reilly KM, Grassly NC. Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. Expert Rev Vaccines 2015;14:1113-23. [PMID: 26159938 DOI: 10.1586/14760584.2015.1052800] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
23 Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012;8:e1002599. [PMID: 22532797 DOI: 10.1371/journal.ppat.1002599] [Cited by in Crossref: 131] [Cited by in F6Publishing: 102] [Article Influence: 14.6] [Reference Citation Analysis]
24 Gorell E, Nguyen N, Lane A, Siprashvili Z. Gene therapy for skin diseases. Cold Spring Harb Perspect Med 2014;4:a015149. [PMID: 24692191 DOI: 10.1101/cshperspect.a015149] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
25 Grassly NC. The final stages of the global eradication of poliomyelitis. Philos Trans R Soc Lond B Biol Sci 2013;368:20120140. [PMID: 23798688 DOI: 10.1098/rstb.2012.0140] [Cited by in Crossref: 51] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
26 Okayasu H, Sein C, Chang Blanc D, Gonzalez AR, Zehrung D, Jarrahian C, Macklin G, Sutter RW. Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization. J Infect Dis 2017;216:S161-7. [PMID: 28838185 DOI: 10.1093/infdis/jix038] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
27 Saitoh A, Aizawa Y. Intradermal vaccination for infants and children. Hum Vaccin Immunother 2016;12:2447-55. [PMID: 27135736 DOI: 10.1080/21645515.2016.1176652] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
28 Muller DA, Pearson FE, Fernando GJ, Agyei-Yeboah C, Owens NS, Corrie SR, Crichton ML, Wei JC, Weldon WC, Oberste MS, Young PR, Kendall MA. Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. Sci Rep 2016;6:22094. [PMID: 26911254 DOI: 10.1038/srep22094] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
29 Kim YC, Prausnitz MR. Enabling skin vaccination using new delivery technologies. Drug Deliv Transl Res 2011;1:7-12. [PMID: 21799951 DOI: 10.1007/s13346-010-0005-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
30 Zhou S, Ren T, Gu H, Wang C, Li M, Zhao Z, Xing L, Zhang L, Sun Y, Yang P, Wang X. Intradermal delivery of a fractional dose of influenza H7N9 split vaccine elicits protective immunity in mice and rats. Hum Vaccin Immunother 2018;14:623-9. [PMID: 29400997 DOI: 10.1080/21645515.2017.1423156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Chen Z, Chumakov K, Dragunsky E, Kouiavskaia D, Makiya M, Neverov A, Rezapkin G, Sebrell A, Purcell R. Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis. J Virol 2011;85:4354-62. [PMID: 21345966 DOI: 10.1128/JVI.02553-10] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
32 Mahmood K, Pelkowski S, Atherly D, Sitrin RD, Donnelly JJ. Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries. Hum Vaccin Immunother. 2013;9:1894-1902. [PMID: 23787559 DOI: 10.4161/hv.25407] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
33 Kim YC, Jarrahian C, Zehrung D, Mitragotri S, Prausnitz MR. Delivery systems for intradermal vaccination. Curr Top Microbiol Immunol 2012;351:77-112. [PMID: 21472533 DOI: 10.1007/82_2011_123] [Cited by in Crossref: 36] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
34 Migliore A, Gigliucci G, Di Marzo R, Russo D, Mammucari M. Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic? Risk Manag Healthc Policy 2021;14:2079-87. [PMID: 34045909 DOI: 10.2147/RMHP.S309707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
35 Dietrich J, Andreasen LV, Andersen P, Agger EM. Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01. PLoS One 2014;9:e100879. [PMID: 24956110 DOI: 10.1371/journal.pone.0100879] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
36 Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010;172:1213-29. [PMID: 20978089 DOI: 10.1093/aje/kwq320] [Cited by in Crossref: 243] [Cited by in F6Publishing: 153] [Article Influence: 22.1] [Reference Citation Analysis]
37 Levin Y, Kochba E, Hung I, Kenney R. Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future. Hum Vaccin Immunother 2015;11:991-7. [PMID: 25745830 DOI: 10.1080/21645515.2015.1010871] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 9.6] [Reference Citation Analysis]
38 Baicus A. History of polio vaccination. World J Virol 2012;1:108-14. [PMID: 24175215 DOI: 10.5501/wjv.v1.i4.108] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
39 Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM. Expert review on poliovirus immunity and transmission. Risk Anal 2013;33:544-605. [PMID: 22804479 DOI: 10.1111/j.1539-6924.2012.01864.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 60] [Article Influence: 8.9] [Reference Citation Analysis]
40 Wright PF, Hoen AG, Ilyushina NA, Brown EP, Ackerman ME, Wieland-Alter W, Connor RI, Jegaskanda S, Rosenberg-Hasson Y, Haynes BC, Luke CJ, Subbarao K, Treanor JJ. Correlates of Immunity to Influenza as Determined by Challenge of Children with Live, Attenuated Influenza Vaccine. Open Forum Infect Dis 2016;3:ofw108. [PMID: 27419180 DOI: 10.1093/ofid/ofw108] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]